Agena Bioscience, Inc., headquartered in the United States, is a leading player in the biotechnology industry, specialising in innovative genomic solutions. Founded in 2006, the company has made significant strides in the development of its proprietary MassARRAY® technology, which enables precise and cost-effective genetic analysis. With a focus on applications in clinical research, oncology, and inherited disease testing, Agena's core products, including the MassARRAY System and a range of assay panels, stand out for their high throughput and flexibility. The company has established a strong market position, recognised for its commitment to advancing personalised medicine and improving patient outcomes. Through continuous innovation and strategic partnerships, Agena Bioscience remains at the forefront of genomic technology, serving a global clientele across major operational regions.
How does Agena Bioscience, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Agena Bioscience, Inc.'s score of 36 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Agena Bioscience, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Mesa Laboratories, Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or specific climate pledges from Agena Bioscience, it is important to note that emissions data and climate initiatives may be inherited from its parent company, Mesa Laboratories, Inc. This relationship suggests that any climate strategies or performance metrics may align with those of Mesa Laboratories, although specific details are not provided. As a part of the broader industry context, companies like Agena Bioscience are increasingly expected to adopt transparent climate commitments and set measurable reduction targets in line with global sustainability goals. However, without specific data or commitments available, it is challenging to assess their current climate impact or future initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 389,800 | 000,000 | 
| Scope 2 | 1,186,230 | 0,000,000 | 
| Scope 3 | - | - | 
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Agena Bioscience, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.